Numerous investigations support decreased glutamatergic signaling as a pathogenic mechanism of schizophrenia, yet the molecular underpinnings for such dysregulation are largely unknown. In the post-mortem dorsolateral prefrontal cortex (DLPFC), we found striking decreases in tyrosine phosphorylation of N-methyl-D aspartate (NMDA) receptor subunit 2 (GluN2) that is critical for neuroplasticity. The decreased GluN2 activity in schizophrenia may not be because of downregulation of NMDA receptors as MK-801 binding and NMDA receptor complexes in postsynaptic density (PSD) were in fact increased in schizophrenia cases. At the postreceptor level, however, we found striking reductions in the protein kinase C, Pyk 2 and Src kinase activity that in tandem can decrease GluN2 activation. Given that Src serves as a hub of various signaling mechanisms affecting GluN2 phosphorylation, we postulated that Src hypoactivity may result from convergent alterations of various schizophrenia susceptibility pathways and thus mediate their effects on NMDA receptor signaling. Indeed, the DLPFC of schizophrenia cases exhibit increased PSD-95 and erbB4 and decreased receptor-type tyrosine-protein phosphatase-α (RPTPα) and dysbindin-1, each of which reduces Src activity via protein interaction with Src. To test genomic underpinnings for Src hypoactivity, we examined genome-wide association study results, incorporating 13 394 cases and 34 676 controls. We found no significant association of individual variants of Src and its direct regulators with schizophrenia. However, a protein-protein interaction-based network centered on Src showed significant enrichment of gene-level associations with schizophrenia compared with other psychiatric illnesses. Our results together demonstrate striking decreases in NMDA receptor signaling at the postreceptor level and propose Src as a nodal point of convergent dysregulations affecting NMDA receptor pathway via protein-protein associations.
INTRODUCTION
Multiple lines of evidence support glutamatergic dysregulation as a key pathogenic mechanism of schizophrenia (SCZ), widely known as the N-methyl-D aspartate (NMDA) receptor (NMDAR) hypofunction hypothesis. [1] [2] [3] This postulate originated from clinical observations in which NMDAR blockade induced psychosis in healthy human subjects and worsened symptoms in patients with SCZ. [4] [5] [6] In addition, rodent studies offered further support demonstrating that NMDAR antagonists or mutation of NMDAR genes induced neurophysiological and behavioral endophenotypes of psychosis. 3, 7, 8 Furthermore, treatment studies demonstrated that clinical manifestations of SCZ in patients and SCZ-like phenotypes in animal models are reduced by enhancement of glutamatergic neurotransmission. 9, 10 Despite the noted evidence for NMDAR hypofunction in SCZ, mechanistic underpinnings for this dysfunction are presently unknown. Presynaptically, decreased D-serine and glutamate carboxypeptidase II, and increased kynurenic acid, were observed in the CSF or post-mortem brains of patients with SCZ. 11, 12 In addition, brain imaging studies in particular have shown alterations in gluthathione. 13 Although some of the results are not fully in concert, these together suggest dysregulations in presynaptic glutamate signaling in SCZ. 1, 13 In search of postsynaptic mechanisms, multiple groups have investigated mRNA or protein levels of NMDAR subunits and their signaling partners in the post-mortem brains of SCZ cases, and have reported various interesting findings, albeit somewhat inconsistent. [14] [15] [16] Given that NMDAR activity arises from the receptor complexes that are targeted to specific subcellular microdomains and involves extensive intracellular signaling mechanisms, 17, 18 here we examined NMDAR activity specifically in synaptic regions and its underlying signaling mechanisms in post-mortem brains.
Glutamate binding to NMDARs activates a cascade of kinases at the postreceptor level (called 'postreceptor kinases' henceforth). It enhances Ca 2+ influx that activates Ca 2+ /calmodulin-dependent kinase II and protein kinase C (PKC). 17, 19 The latter phosphorylates proline-rich tyrosine kinase 2 (Pyk2), leading to activation of the sarcoma tyrosine kinase known as Src. 20, 21 Conversely, postreceptor kinases in turn regulate NMDAR channel activity via tyrosine phosphorylation of GluN2 subunits, critical for sustained enhancement of channel activity in synaptic plasticity. 22 Thus, NMDARs and their downstream postreceptor kinases are interdependent for their activation, forming a loop of cascade: NMDAR → PKC → Pyk2 → Src → pYGluN2. Of the postreceptor kinases in this cascade, Src plays a primary role as it directly phosphorylates GluN2 subunits as a molecular hub of various signaling pathways, including those outside the NMDAR pathway, affecting tyrosine phosphorylation of GluN2. As such, Src serves as a conduit for various non-NMDAR signaling mechanisms that regulate tyrosine phosphorylation of GluN2 and synaptic plasticity-related NMDAR function. 18 Residing in the postsynaptic density (PSD), synaptic NMDARs are associated with scaffolding proteins and many signaling molecules and comprise a macromolecular receptor complex. 23, 24 Hence, the NMDAR complex can reflect alterations in diverse signaling pathways, including those implicated for SCZ. Increasing genetic evidence indeed supports this possibility. Among genetic variants found to be associated with SCZ are those of DTNBP1, 25 
DISC1
, 26 ERBB4, 27 neuregulin 1 (NRG1) 28, 29 and PTPRA, 30,31 whose gene products can affect NMDAR complexes. 26, 28, 30 Moreover, genome-wide investigation of de novo copy number variations as well as de novo mutations point to multiple genes within NMDAR/ activity-regulated cytoskeleton-associated (ARC) complexes, 32, 33 suggesting that NMDAR complexes may serve as molecular substrates upon which various SCZ susceptibility factors converge. A critical next step then will be to delineate molecular underpinnings for NMDAR hypofunction in SCZ and to identify the mechanisms of convergence in the brain of patients with SCZ.
Previously, we reported that NMDA/glycine-induced tyrosine phosphorylation of GluN2 subunits, critical for sustained enhancement of NMDAR activity, was decreased in the dorsolateral prefrontal cortex (DLPFC) of SCZ subjects as compared with controls. 28 Tyrosine phosphorylation of GluN2 subunits is governed by Src kinase 22 that can serve as a molecular hub of alterations in various signaling pathways including the SCZ susceptibility pathways. 22 Indeed, NRG1, ErbB4, PSD-95, dysbindin-1 or RPTPα, each of which has been implicated for SCZ, can modulate Src kinase. 22, 31, 34, 35 These together led us to hypothesize that Src kinase may mediate convergent dysregulations of various SCZ susceptibility pathways to reduce tyrosine phosphorylation of GluN2 and thereby precipitate NMDAR hypoactivity.
Examination of receptor activity and intracellular signaling is a methodological challenge in post-mortem studies. We developed several novel methodologies to quantify NMDAR signaling activity, protein-protein interactions (PPIs) in NMDAR complexes and the enzyme activity of Src in post-mortem brain tissue. 28, 34, 36 A matched-pairs design was used to minimize the effects of age and sex in observed differences between SCZ and control cases. We focused on the DLPFC because disruption of this brain area is common in SCZ, 37, 38 contributes to deficits in selective attention, working memory and executive function in this disorder 37, 39, 40 and has been shown to display NMDAR hypofunction in SCZ. Here, we present evidence pointing to the postreceptor segment of the NMDAR pathway as a locus of dysregulation in the DLPFC of SCZ cases and demonstrate that Src hypoactivity, resulting from convergent alterations of susceptibility pathways, mediates reduction of tyrosine phosphorylation of GluN2 in the DLPFC of SCZ cases.
MATERIALS AND METHODS

Post-mortem brains
Flash-frozen DLPFC tissues from 17 pairs of SCZ subjects and of controls, matched for age, sex and post-mortem interval, obtained from the Penn Brain Bank at the University of Pennsylvania, were used for the study. Approved by the Institutional Review Board at the University of Pennsylvania, subjects were prospectively diagnosed by DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) criteria and consents for autopsy were obtained from the next of kin or a legal guardian. Subjects with a history of substance abuse, neurological illnesses or the need for ventilator support near death were excluded. Neuropathological assessments were performed on the PFC of all subjects to exclude cases with gross neurodegenerative process and abnormal levels of senile plaques or Lewy bodies (additional details are in Supplementary Data). Detailed demographic data are shown in Supplementary Table S1 and S2.
Animal studies
Rodent tissues examined in this study included PFC tissues from homozygous sdy mice (n = 6), 41 from Ptpra − / − -null mice (n = 7) 31 (provided by Jan Sap (University of Paris, Paris, France) and Catherine Pallen (University of British Columbia, Vancouver, BC, Canada) respectively) and from antipsychotic-treated rhesus monkeys (n = 8/9) (provided by Scott E Hemby, Wake Forest University, Winston-Salem, NC, USA; see treatment details in Supplementary Figure S2 ). All protocols were approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania and all experiments on mice were conducted in accordance with the University Laboratory Animal Resources guidelines.
MK-801 assay
As previously described, 42 10 μg of P2 membrane extracts were incubated with varying concentrations of [ 3 H]MK-801 (Perkin Elmer, Waltham, MA, USA), ranging from 0 to 60 nM, in the presence of 1 μM gycine, 10 μM glutamate and 10 μM spermidine in 5 mM Tris-HCl (pH 7.4). The samples were incubated at 30°C for 2 h and the reactions were precipitated on GF/C (GE, Pittsburgh, PA, USA) glass filters and radioactivity was measured using Scintiverse cocktail (Fisher Scientific, Fair Lawn, NJ, USA) in a liquid scintillation counter (Pharmacia, Peapack, NJ, USA).
Post-mortem brain receptor activation
Tissue slices (100 μm) from DLPFC of frozen post-mortem brains were incubated with 1 μM glycine and 10 μM NMDA for 30 min at 37°C and synaptosomal fractions (S) were prepared as previously described in detail. 28, 43 Src kinase assay P2 protein extracts (10 μg) were incubated with 1 mM of EPQ(pY)EEIPIA, which activates src, or EPQYEEIPIA (Anaspec, Fremont, CA, USA), control peptide, overnight at 4°C. Src kinase activity was determined by measuring incorporation of γATP in the peptide substrate provided by the manufacturer (Millipore, Billerica, MA, USA) in liquid scintillation counter (Pharmacia, Peapack, NJ, USA).
Tissue fractionation PSD fractions were isolated from flash frozen coronal slabs of the DLPFC, including Brodmann areas 9 and/or 46, by the method previously described in detail 36 
Src binding assay with biotinylated peptide
First, Src proteins were affinity purified from synaptic membranes of the DLPFC of SCZ and CTRL cases using Src antibodies. The EPQ(pY)EEIPIA and EPQYEEIPIA peptides (Anaspec) were biotinylated following the protocol by Thermo Scientific (Fremont, CA, USA). Then, 1 μg of purified Src proteins was incubated with biotinylated peptides at 30°C for 30 min. The reaction was terminated using ice-cold immunoprecipitation buffer and incubated with 20 μl of Nutravidin beads at 4°C for 60 min. Pelleted beads were analyzed by western blotting with streptavidin-horseradish peroxidase conjugate.
GWAS data sets
The SCZ data set consisted of the results of a genome-wide association study (GWAS) meta-analysis of 15 cohorts that included 13 394 cases, of which 11 985 were classified as schizophrenia, 377 as schizoaffective and 1032 as bipolar, and 34 676 controls (described in Sleiman et al.
44
). Singlenucleotide polymorphisms (SNPs) with missing data in more than two cohorts were excluded from further analysis. The major depressive disorder Src kinase hypoactivity in schizophrenia A Banerjee et al (MDD), bipolar disorder (BP) and attention deficit hyperactivity disorder (ADHD) data sets were downloaded from the Psychiatric Genomics Consortium (PGC) website (http://www.med.unc.edu/pgc) and consisted of 9240 MDD cases and 9519 controls; 45 7481 BP cases and 9250 controls; 46 2064 ADHD trios, 896 ADHD cases and 2455 controls. 47 The Crohn's disease (CD) data set comprised 3685 cases and 5968 controls. 48 Gene-level associations Gene-level associations were calculated using VEGAS. 49 VEGAS performs Monte Carlo simulations from the multivariate normal distribution based on the patterns of linkage disequilibrium in a reference population and assigns an estimated P-value to each gene. SNPs located within 50 kb upstream and 50 kb downstream of gene boundaries were included in the analysis in order to capture regulatory regions and SNPs in linkage disequilibrium. Gene-level significance was set at P ≤ 0.05.
PPI network analysis
The PPI network was constructed based on indices of protein interactions derived from primary interaction databases including BIND, BioGRID, CORUM, DIP, HPRD, InnateDB, IntAct, MatrixDB, MINT, MPact, MPIDB, MPPI and OPHID as compiled by iRefindex. 50 To control the false positive rate, only human-human protein interactions supported by at least two publications listed in PubMed were considered for this study. Based on the PPIs we constructed a network of the Src pathway genes and their interactors ( Figure 5b ). The resulting Src network consisted of 30 genes.
Enrichment analysis
To test whether the src PPI network was enriched for genic association with SCZ, we generated gene-level P-values for each of the 30 genes using VEGAS from 5 separate GWAS data sets including SCZ, MDD, BP, ADHD and a non-psychiatric disease, CD. To determine enrichment of significance, we identified all SNPs within each of the 30 genes, including all SNPs 50 kb upstream and downstream of the genes, as was done to generate genelevel significance for each of the data sets separately. Total SNP numbers varied between each of the studies depending on the genotyping platform. SNP-level significance was set at P ≤ 0.05. Enrichment of association between SCZ and each of the four other phenotypes was tested using two-tailed Fisher's exact test as well as between CD and the four psychiatric disorders. Because of the low cell counts in the gene-level associations, enrichment statistics were generated on individual singlenucleotide variations within the genes.
RESULTS
This study employs multiple methods that were devised specifically to assess NMDAR function in post-mortem brains. 28, 36, 43, 51 We conducted extensive preliminary work 28, 36, 43, 51 to verify the stability of these measures in post-mortem tissues, with special attention to the range of ages, antipsychotic doses and post-mortem interval of our cases in human (Supplementary Figure S1 ), rodent and monkey brains (Supplementary Figures S2-S4 ). The post mortem study was conducted on 17 SCZ cases (Supplementary Tables S1-S2) , each matched to a normal control of the same sex, similar age (80.12 ± 1.40 years (mean ± s.d.) for SCZ cases vs 79.53 ± 2.31 years for controls), equivalent pH (6.56±0.039 for SCZ cases vs 6.59 ± 0.089) and comparable, low post-mortem interval (12.12 ± 0.98 h vs 8.76 ± 0.08 for controls).
NMDAR complexes are increased in the PSD of SCZ cases The abundance of NMDAR complexes was assessed in synaptic membranes of the DLPFC using a binding assay with the noncompetitive NMDAR antagonist MK-801 in the presence of glutamate and glycine. 52, 53 The B max for MK-801 binding showed that the NMDAR density in SCZ cases was ∼ 30% higher than that in controls (Figures 1a and b, t(13) = 2.837, P = 0.014). To test whether such increases in NMDAR complexes occur in the PSD, the PSDenriched fractions were isolated from the DLPFC and protein associations in NMDAR complexes were assessed using immunoprecipitation experiments for GluN1 or PSD-95. The results showed a higher level of PSD-95 in GluN1 immunoprecipitates (t(13) = 2.279, P = 0.0389, Figures 1c and d) , and a higher level of GluN1 in PSD-95 immunoprecipitates in SCZ brains (t(13) = 2.405 P = 0.0318, Figures  1c and d) . These results indicate increased number of NMDAR complexes in the PSD of SCZ cases, which may not be a likely explanation for decreased tyrosine phosphorylation of GluN2. Thus, we turned our attention to molecular events downstream to the receptors, that is, the postreceptor level.
NMDAR signaling is hypoactive at the postreceptor level in schizophrenia We measured NMDAR signaling responses to 10 μM NMDA+1 μM glycine applied to 50 μm thick slices from the DLPFC of patients and healthy matched controls. SCZ cases showed decreases in NMDA/glycine-induced tyrosine phosphorylation of GluN2 that is critical for NMDAR channel activity (P = 0.001, t(11) = 6.066, Figures  2a and b) . Next, we examined PKCγ, phospholipase C-γ (PLCγ) and Src that in tandem govern tyrosine phosphorylation of GluN2. In synaptic membranes derived from the tissues that were incubated with NMDA/glycine, we found decreases in GluN1 association with PLCγ and PKCγ 54, 55 (Figures 2a and b ; P = 0.042, t(11) = 2.303 for pY 419 Src and P = 0.002, t(11) = 4.171 for pY 530 Src). These results together demonstrate that the activity of postreceptor kinases PKC, Pyk2 and Src is attenuated in the DLPFC of SCZ cases.
All parameters of NMDAR signaling described above were derived from membrane fractions that incorporate NMDAR complexes in synaptic as well as extrasynaptic regions. To test whether the altered NMDAR signaling occurs in the synaptic region, we examined PSD fractions of the DLPFC. In PSD fractions, the activity of postreceptor kinases is difficult to assess because of the presence of detergents, but protein associations resulting from the activity of kinases can be measured. We examined PSD fractions for NMDAR association with PLCγ and PKCγ 54,56 as surrogate measures of GluN2 activation that was significantly reduced in the SCZ cases compared with controls (Figure 2e and f; P o0.0104, t(13) = 2.991 for PLCγ and P o 0.004, t(13) = 3.434, for PKCγ). This indicates that synaptic NMDAR complexes are hypoactive in the DLPFC of SCZ cases.
Src hypoactivity occurs independently of its upstream kinases in the NMDAR pathway As noted above, Src serves as a molecular hub for various non-NMDAR signaling mechanisms affecting tyrosine phosphorylation of GluN2, including NRG1, erbB4 and RPTPα, SCZ susceptibility pathways. Based on this, we hypothesized that Src hypoactivity is not merely a result of hypofunction of upstream kinases within the NMDAR pathway but integrates alterations in signaling pathways that are not canonical components of the NMDAR pathway. We first tested whether Src hypoactivity is present in SCZ cases when Src activity is assessed independently of activation of NMDAR. In studies represented in Figure 2 , postreceptor NMDAR signaling was assayed in response to NMDAR activation, and thus the results cannot resolve whether Src hypoactivity results from alterations at the receptor level or from the postreceptor segment. To distinguish between these two possibilities, we assessed Src activity with and without NMDAR activation in postmortem tissues. First, DLPFC slices were incubated with NMDA+glycine so that NMDAR complexes were activated and Src kinase activity was measured (Figure 3a) . Second, we isolated synaptic membranes from the DLPFC tissues, that were then incubated with the peptide that directly activates Src, EPQ(pY)EEIPIA, instead of NMDA+glycine 34, 35 (Figure 3b ). NMDA+glycine and EPQ(pY)EEIPIA both enhanced Src activity. EPQ(pY)EEIPIA increased Src enzyme activity on average 3.02 ± 0.37-fold in the control group, but only by 1.75 ± 0.30-fold on average in the SCZ group (Figure 3b ; P = 0.022, t(16) = 2.859). As predicted, we found a corresponding reduction in basal levels of activated Src (pY 419 ) in the patient group compared with controls ( Figures 3c and d , P = 0.015, t (13) = 3.230), whereas Src protein levels remained unaltered. Of particular note, DLPFC tissue from the SCZ patients showed levels of Pyk2 and its activated form (pY 402 Pyk2) that were comparable to those of the control group (Figures 3c and d) . These findings indicate that Src hypoactivity in SCZ cannot be explained fully by upstream abnormalities in the NMDAR → PKC → Pyk2 → Src cascade. As Src hypoactivity is independent of upstream kinases, we next determined the binding capacity of Src for its activators.
Binding capacity of Src for activated upstream kinases is decreased in SCZ We isolated Src from DLPFC tissues and then assessed binding of these kinases to biotinylated EPQ(pY)EEIPIA. The SCZ group showed a significantly lower association of Src with EPQ(pY)EEIPIA at 0.1, 1.0 and 10 nM of the substrate (Figures 4a and b , P = 0.013, t(11) = 2.945 for 0.1 nM; P = 0.024, t(11) = 2.620 for 1 nM; P = 0.049, t(11) = 2.213 for 10 nM). Thus, the binding capacity of the SH-2 domain in Src is decreased in SCZ, decreasing Src activity independently of the NMDAR → PKC → Pyk2 cascade. The next step was to identify molecular alterations that may affect the binding capacity of Src and/or its association with its activators.
Convergent molecular alterations reduce Src binding with upstream kinases in SCZ
We found a number of molecular alterations in the DLPFC of SCZ cases that can affect Src association with its activators. RPTPα increases the activity of Src via dephosphorylation of SrcY 530 . 30 RPTPα association with Src, assessed in PSD-95 immunoprecipitates, was significantly decreased in SCZ cases (Figures 4c and d , P = 0.006, t(11) = 3.390). Given that the N-terminal of PSD-95 can interfere with Src binding with its activators, 34 increased PSD-95 in NMDAR complexes as shown in the DLPFC of SCZ cases ( Figures  1c and d ) may be another molecular underpinning for Src hypoactivity activity. In addition, increased erbB4 signaling, either via altered expression 57 or cleavage of NRG1 58 or erbB4 activity, is expected to decrease Src activity. Indeed, Src -NMDAR complexes captured by PSD-95 exhibited increased erbB4 in the SCZ group (P=0.0413, t(13)=2.246) (Figure 4c and d) . GluN1 association with PSD-95 was increased in the GluN1 complexes (black bar; P ≤ 0.038) and PSD-95 association with GluN1 (black bar; P ¼ 0.031) was increased in PSD-95 complexes in the SCZ group. All data are means ± s.e.m., Student's paired t-test, two tailed. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
We next further examined whether these dysregulations can indeed lead to Src hypoactivity. ErbB4 suppresses Src activity 28, 35 and is increased in PSD-95-Src complexes derived from the DLPFC of SCZ subjects (Figures 4c and d) . We predicted that activation of erbB4 via NRG1 would lead to a greater reduction in Src activity of SCZ cases than of controls. Indeed, NRG1-induced suppression of Src activation was more pronounced in SCZ cases compared with controls ( Figure 4e , P = 0.005, t(11) = 3.433). Hence, the decreased RPTPα in PSD-95-Src complexes as observed in SCZ (Figures 4c  and d) should decrease Src activity. Indeed, mice lacking RPTPα, which were found to display several SCZ phenotypes, 31 also exhibit Src hypoactivity (Figure 4e , P = 0.015, t(8) = 2.3114). Dysbindin-1, encoded by DTNBP1, is another molecule that is decreased in the DLPFC of SCZ cases. 59 Mice lacking dysbindin-1 due to deletion mutation in Dtnbp1 (sdy − / − ), which show several SCZ phenotypes 59 as well as NMDAR hypofunction, 60 also exhibited Src hypoactivity (Figure 4e , P = 0.0021, t(7) = 4.728).
A PPI-based Src network is associated with SCZ We next asked whether the molecular alterations in PSD-95, erbB4, RPTPα or dysbindin in the DLPFC of SCZ cases could be genetically determined. We conducted a meta-analysis of SCZ GWAS studies, consisting of 15 cohorts that included 13 394 cases and 34 676 controls. Src, PKCγ, Pyk2, PSD-95 and RPTPα (Src, PRKCG, PTK2B, DLG4 and PTPRA) as well as other direct interactors of Src showed no evidence of SNP or gene-level associations (Figure 5a ). Given our results suggesting that Src hypoactivity results from altered protein association of Src with its interactors, we hypothesized that a wider PPI-based Src network may be associated with SCZ. We generated a PPI network centered around Src that consisted of 30 genes ( Figure 5 , Supplementary Table S3 in Supplementary Information). Of these, 14 showed gene-level significant association with SCZ (Figure 5b ). To determine whether the observed gene-level associations in the Src network is specific to SCZ, we (pYGluN2) is attenuated in SCZ compared with control (P = 0.001). pY419 Src is decreased and pY530 Src is increased in GluN2 complex in SCZ (P = 0.042 and P = 0.016, respectively). (c, d) Ligand-induced enhancement of GluN1 association with its signaling partners, phospholipase C-γ (PLCγ) and protein kinase C-γ (PKCγ), is reduced in SCZ subjects compared with their controls (P = 0.027 and P = 0.026, respectively). Tyrosine phosphorylation of 402Pyk2 (P = 0.029) and 419Src (P = 0.0435) are also decreased in SCZ subjects in GluN1 complexes. (e, f) Postsynaptic density (PSD) fractions from the DLPFC of 14 matched pairs were immunoprecipitated with antibody for GluN1. Association of GluN1 with PLCγ (P = 0.010) and PKCγ (P = 0.004) is decreased in the SCZ group (black bar) compared with that of the control (white bar). All data are means ± s.e.m., Student's paired t-test, twotailed. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. compared the association results of a SCZ GWAS meta-analysis against the results of four other data sets: MDD, BP, ADHD and CD. The enrichment of SNP associations within the Src network of 30 genes was significant in schizophrenia compared with all other phenotypes (SCZ vs MDD P = 6.921 × 10 − 11 ; SCZ vs ADHD P = 3.429 × 10 − 12 ; SCZ vs BP P = 9.338 × 10
; SCZ vs CD P = 7.47 × 10 − 7 ); individual SNP counts for each of the five diseases are listed in Supplementary Table S4 (See Supplementary Information).
DISCUSSION
The goal of this study was to delineate the alterations in postsynaptic NMDAR signaling in SCZ and to investigate its underlying mechanisms. Our results point to the postreceptor kinases as a locus of dysregulation in SCZ and suggest that Src hypoactivity may mediate convergent abnormalities of susceptibility pathways to decrease tyrosine phosphorylation of GluN2 subunits.
NMDAR hypofunction can result from decreased number of NMDAR complexes, which has been extensively tested in previous studies. [14] [15] [16] Our approach was to measure the number of NMDAR assemblies in the synaptic region by MK-801 binding assays of synaptic membranes and by immunoprecipitation of the core scaffold of NMDAR complexes, the GluN1-PSD-95 associations. Our findings of increased MK-801 binding and NMDAR complexes in the PSD suggest that NMDAR hypofunction in SCZ may not result from decreases in NMDAR complexes in synaptic regions.
At the postreceptor level, however, we found robust reductions in multiple parameters indicative of hypoactive NMDAR signaling. These include decreases in (1) the activity of PKCγ, Pyk2 and Src, (2) tyrosine phosphorylation of GluN2 subunits and (3) NMDAR association with its signaling partners, PLCγ and PKCγ. These three parameters are interconnected since the postreceptor kinases enhance tyrosine phosphorylation, which in turn recruits PLCγ into NMDAR complexes (Figure 5c ). Consistent reductions in these three interconnected parameters therefore point to this specific segment of the NMDAR pathway, namely the postreceptor kinases, as a locus of dysregulation in SCZ.
The reduced postreceptor kinase activities as observed in SCZ cases could potentially result from presynaptic alterations, 1 such as decreased glutamate release or increased kynurenic acid observed in SCZ cases. 11, 12 Our assessment of postreceptor kinase function, however, is based on applying relatively high concentrations of NMDA and glycine, conditions under which assay results may not capture presynaptic alterations. Thus, dysregulations in postreceptor kinases as assessed in this study are unlikely to reflect presynaptic dysregulations.
It is possible that these postreceptor kinase dysregulations are secondary to ante-mortem medication effects. In particular, previous studies have shown that chronic clozapine treatment decreased the activity and/or expression of PKC and PLCγ. 57 We therefore examined these signaling molecules in rhesus macaques (age range: 5.9-7.9 years) that were treated with a low dose of haloperidol (0.07 mg kg showed trends for increase or no changes in the three treatment conditions (Supplementary Figure S2 and Supplementary Information). Thus, decreases in GluN1's association with PLCγ and PKCγ in SCZ are unlikely to be the result of antipsychotic treatment.
Among the postreceptor kinases, Src is of particular interest as it directly phosphorylates tyrosine residues of GluN2 and therefore serves as a point of convergence for various pathways affecting NMDAR signaling. 22, 61 Our results offer multiple lines of evidence supporting the notion that Src hypoactivity is a mere result of hypoactivity of upstream kinases in the NMDAR pathway. Specifically, Src activity was decreased in SCZ cases even when measured under the condition that NMDARs were not activated and Src binding capacity was also reduced, independent of the NMDAR → PKC → Pyk2 cascade. These findings strongly suggest that Src hypoactivity may result from changes in molecular events that are outside of the canonical components of the NMDAR pathway. were immunoprecipitated with antibodies for PSD-95. RPTPα is decreased but erbB4 is increased in the PSD-95 complexes derived from SCZ (black bars) subjects (P = 0.006 for RPTPα and P=0.041 for ErbB4), whereas csk or Src are not altered. In addition, the ratios of PSD-95 with respect to GluN1 were increased in the N-methyl-D aspartate receptor (NMDAR) complexes derived from PSD fractions (Figure 1c and d) . (e) Increased NRG1-erbB4 signaling and decreased expression of RPTPα and dysbindin decrease Src activity. NRG1-mediated Src activity measured by 32P-γATP incorporation in the presence of NMDA/glycine was decreased in the DLPFC of human post-mortem brains (n = 12; P ≤ 0.005). Src activity was also measured in presence of Src-SH2 binding pY peptide, EPQ(pY)EEIPIA in dysbindin (sdy − / − ) and RPTPα (Ptpra − / − ) knockout mice. In both sdy − / − and Ptpra − / − mice, Src activity was attenuated compared with the wild type. In sdy − / − mice, src activity was decreased by~37%, (n = 6; P ≤ 0.002), whereas it was decreased in Ptpra − / − mice by~47%, (n = 7; P ≤ 0.015). All data are means ± s.e.m., Student's paired t-test, two tailed. The protein interaction-derived Src subnetwork in the SCZ and Crohn's disease cohorts. 48 Based on protein-protein interactions previously reported, a subnetwork of Src was constructed that consists of 30 genes. In this illustration, nodes represent genes in the subnetwork and connecting lines (or edges) show previously reported direct protein interactions. Derived from brain expression data from the Allen Brain Atlas, the information on the degree of coexpression between the proteins is incorporated into the connecting lines. The width of connecting lines corresponds to the strength of the degree of coexpression between the proteins, with solid lines signifying positive, and dotted lines negative correlations. Of the 30 genes in the subnetwork, 14 showed gene-wise significance in the schizophrenia cohort, whereas only 3 showed gene-wise significance in the Crohn's disease cohort. Gene-wise P-value significance is denoted on a green to red color scale. Circled nodes are genes with single-nucleotide polymorphisms (SNPs) that had P-values o 1 × 10 − 3 for genetic association with the illness and all others are boxed. (c) Summary diagram: Src serves as a nodal point for various molecular alterations in the dorsolateral prefrontal cortex (DLPFC) of SCZ cases, leading to reduced postreceptor N-methyl-D aspartate receptor (NMDAR) activity. (1) NRG1-erbB4 signaling can reduce Src activity, 35 and therefore the increased NRG1-erbB4 signaling as shown in SCZ cases 28 will decrease Src activity (Figure 4e ). (2) Postsynaptic density protein-95 (PSD-95) decreases Src activity 34 and thus the increased PSD-95 in NMDAR complexes in SCZ cases (Figure 1c ) will reduce Src activity. (3) Receptor-type tyrosine-protein phosphatase-α (RPTPα) increases Src activity and thus decreased RPTPα in SCZ cases (Figure 4d ) will reduce Src activity, (4) Sdy − / − mice, mutated for dysbindin, exhibit reduced Src activity. Decreased dysbindin 1, as previously seen in SCZ cases, 59 can be another underlying mechanism for Src hypoactivity. Src hypoactivity precipitated by these convergent dysregulations (arrows in red) will reduce phosphorylation of its substrate, the GluN2 subunits, that is critical for the channel activity of NMDARs, as well as its downstream signaling (arrows in blue). Symbols → and ⊥ indicate positive or negative regulation of Src activity by the molecule or the pathway. Downward or upward arrows (blue) indicate alterations of the function of the molecules in the post-mortem DLPFC in SCZ cases.
Indeed, the DLPFC of SCZ cases exhibit a number of molecular alterations that can precipitate Src hypoactivity (Figure 5c ). First, we found decreased RPTPα in Src-NMDAR complexes in SCZ cases. This will lead to Src hypoactivity, as RPTPα enhances Src activity by decreasing phosphorylation of pY530 of Src. 30 Second, as PSD-95 can inhibit Src activity, 34 increased PSD-95 in NMDAR-Src complexes in SCZ cases will also precipitate Src hypoactivity. Third, NRG1-erbB4 signaling can reduce Src activity, 35 and we found increased erbB4-PSD-95 association in SCZ cases. Finally, decreased dysbindin 1 shown in DLPFC of SCZ cases 59 may decrease Src activity as observed in the case of sdy − / − mice. Based on these findings, we propose that Src serves as a nodal point for these molecular alterations in susceptibility pathways leading to decreased GluN2 tyrosine phosphorylation (Figure 5c ).
It will be important to ask whether Src hypoactivity arises from genomic effects. A meta-analysis of 15 cohorts demonstrate that common variants of the core members of the Src pathway, Src, PRKCG, PTK2B, DLG4, CSK, and PTPRA, are not associated with SCZ. This is not unexpected as the expression of these genes in the DLPFC of SCZ cases was comparable to that of control subjects (data not shown). The results from the PPI-based gene association study, however, suggest that a wider PPI-based network centered on Src consisting of 30 genes showed significant enrichment of gene-level associations with SCZ compared with other diseases ( Figure 5 ). Together, these genetic findings are consistent with the notion that the Src pathway as a whole is associated with SCZ, not via common variants of Src or its direct interactors but via proteinprotein associations with a wider network.
Src-mediated tyrosine phosphorylation of GluN2 is critical for the synaptic plasticity (long-term potentiation), [62] [63] [64] [65] the substrates for learning and memory. Thus, Src hypoactivity and its downstream effects observed in the DLPFC can be a basis for deficits in the neurocognitive functions modulated by the DLPFC, such as the working memory and executive function. We propose Src hypoactivity as a nodal mechanism for integrating convergent dysregulation in SCZ susceptibility pathways to reduce NMDAR activity ( Figure 5c ) and suggest that the Src pathway, particularly protein interactions therein, be considered as a novel therapeutic target for SCZ.
